netFormulary NHS
South Staffordshire Joint Formulary
Cannock Chase Clinical Commissioning Group
East Staffordshire Clinical Commissioning Group
South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group
Stafford and Surrounds Clinical Commissioning Group
 Search
 Results

Looking for Atezolizumab found 9 matches

Open monograph to display formulary status BNF Category
  Atezolizumab  (Tecentriq) Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (08.02.03)
link in drug section NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (08.02.03)
link in drug section NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (08.02.03)
link in drug section NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (08.02.03)
link in drug section NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (08.02.03)
link in drug section NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer  (08.02.03)
link in drug section NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (01.01)
link in drug section NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (08.02.03)


 

netFormulary